Method for treatment of patients with hemorrhagic fever with renal syndrome in case of liver dysfunction development

FIELD: medicine.

SUBSTANCE: invention is designed to treat patients with hemorrhagic fever with renal syndrome (HFRS), accompanied by liver dysfunction. As part of basic therapy, intravenous dropwise introduction of 400 ml of remaxol is provided once a day for 10 days. Additionally, as a part of complex therapy, cytoflavin is administered orally twice a day (2 pills) and 250 mg of methionine hepatoprotector is introduced 3 times a day for 20 days.

EFFECT: method allows reduce the duration of the disease, reduce manifestations of intoxication and cytolytic syndromes, and improve the quality of life of patients.

8 tbl, 1 ex

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to organic chemistry, namely to benzimidazole-4-carboxamide derivatives of formula , wherein X means an alkenyl group C2-C7 substituted by two methyls, nitro-radical mono-substituted thienyl, unsubstituted quinolinyl, unsubstituted indolyl, unsubstituted pyridazinyl, unsubstituted piperazinyl, C1-C6-alkyl disubstituted piperazinyl, unsubstituted piperidinyl, unsubstituted pyrazinyl, unsubstituted imidazolyl, unsubstituted pyrimidinyl, phenyl monosubstituted pyrimidinyl, pyrimidinyl disubstituted by an amine radical and a radical specified in a group containing -F, -Cl, -Br or -I, hydroxyl trisubstituted phenyl, methoxy-radical trisubstituted phenyl, hydroxyl and methoxy-radical disubstituted phenyl, pyrazolyl disubstituted by a radical specified in a group containing a C1-C6-alkyl, and by a radical specified in a group containing -F, -C1, -Br or -I; Y means aminophenyl monosubstituted by a radical of -F, -O, -Br or -I phenyl, hydroxyethyl disubstituted by hydroxymethyl or C1-C6-alkyl and phenyl monosubstituted by a nitro group, an amino group or a halogen atom; Y also means unsubstituted piperazinyl, unsubstituted pyridyl, unsubstituted pyrazinyl, C1-C6-alkyl monosubstituted thiazol, unsubstituted pyrimidinyl, unsubstituted purinyl. The invention also refers to a pharmaceutical composition based on the compound of formula (I), using the compound of formula (I), a method for producing the compound of formula (I).

EFFECT: there are prepared new benzimidazol-4-carboxamide derivatives possessing antiviral activity.

5 cl, 6 dwg, 4 tbl, 688 ex

FIELD: medicine.

SUBSTANCE: invention represents an oral anti-enteroviral and immunostimulant agent in the form of capsules containing interferon and additives, differing by the fact that a therapeutic substance is human recombinant interferon alpha-2b immobilised on polyethylene glycol, having a molecular weight of 1.5 kD by a physical method of binding by an accelerated electron flow in a dose of 1.5 Mrad. The ingredients in the agent are taken in a certain ratio.

EFFECT: extending the range of anti-enteroviral agents possessing immunostimulant properties.

6 ex, 10 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and concerns using rhCC10 protein for preparing a therapeutic agent for the therapeutic or preventive effect on influenza virus.

EFFECT: invention provides reducing a pulmonary titre of influenza virus.

11 cl, 4 dwg, 1 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmacology, in particular, to medication, possessing antiviral, antimicrobial, immunomodulating and anti-inflammatory action, in form of drops, spray, gel and solution for injection for treatment and prevention of infection diseases: herpes, acute respiratory viral infections, hepatitis, HIV-infections, viral disease. Medication according to invention contains complex of cytokines with Trilonum B, immobilised on biologically compatible polymer as carrier.

EFFECT: obtaining medication, possessing antiviral, antimicrobial, immunomodulating and anti-inflammatory action.

3 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to 5,5-condensed heteroarylene compounds IIIB, where U2, V1, V2 and W1 are selected from O, N, NH, S or CR3a; U1, W2, X1 and X2 represent C or N; R1 and R2 represents hydrogen, -C(O)CH(NR1bR1c)R1a, -C(O)CH(N(R1c)C(O)OR1b)R1a or -C(O)OR1a; R3a represents hydrogen or R3; R3 represents halogen or -C(O)OR1a; L1 and L2 are such as given in invention formula, each Z1 and Z2 represents bond or -O-; each Rla, R1b and R1c represents hydrogen, C1-6 alkyl or C6-14 aryl; or Rlb and Rlc together with N atom, which they are bound to, form 5-6-membered heterocyclyl; q, r, s, t and u equal 1. Invention also relates to pharmaceutical compositions, containing 5,5-condensed heteroarylene compounds, and methods of treating or preventing HCV infection.

EFFECT: 5,5-condensed heteroarylene derivatives, possessing inhibiting activity with respect to hepatitis C virus.

43 cl, 42 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a novel compound - N,N-bis(1-adamantyl-1-ethylamine) hydrochloride of the structural formula I and a method for production thereof. Compound has biological activity and can be used as a component of a medicinal agent or as an impurity label of a medicinal agent as a standard sample in analytical chemistry of pharmaceutical preparations. A method of producing a compound of formula I includes a) obtaining 1-adamantyl-1-ethylamine from 1-adamantyl-1-ethylamine hydrochloride, b) obtaining a Schiff base of structural formula III by treating with a compound obtained at step (a) with acetyl adamantane, c) treating the Schiff base of formula III with a reducing agent to obtain bis(1-adamantyl-1-ethylamine) hydrochloride of formula I. The compound is characterised by a boiling point, IR, NMR and a mass spectrum data.

EFFECT: improved method.

2 cl, 8 dwg, 1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to N-adamantylbenzotriazole derivatives

and where R1 and R2 are hydrogen or a nitro group. The invention also relates to a method of producing the compound of formulae 1 and 2.

EFFECT: obtaining novel N-adamantylbenzotriazole derivatives which exhibit anti-influenza A virus activity.

3 cl, 5 ex

FIELD: medicine.

SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.

EFFECT: drops possess pronounced antiviral and immunomodulatory effects.

15 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: method includes treating crushed Echinacea purpurea (L.) Moench roots and rhizome with steam, extraction with ethyl alcohol, then steeping, stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench roots and rhizome, after draining a portion of the extract, adding ethyl alcohol to the treated material, draining the whole extract; extracting crushed Echinacea purpurea (L.) Moench herbs with ethyl alcohol, steeping, then stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench herbs, after draining a portion of the extract, adding ethyl alcohol to the treated herbs, draining the whole extract; all obtained extracts are mixed, cooled and filtered under certain conditions. An Echinacea purpurea (L.) Moench tincture. Use of the method to obtain an Echinacea purpurea (L.) Moench tincture.

EFFECT: method preserves the biological activity of components of the tincture and medicinal properties.

3 cl

FIELD: medicine.

SUBSTANCE: invention represents an encapsulated liposomal antiviral agent based on human interferon alpha-2b for vaginal application, characterised by the fact that each capsule is made in the form of a hollow coating, which encloses a powder excipient and liposomes distributed in the excipient, and sodium alginate, a water-soluble polymer gel former; the excipient consists of lactose, sodium chloride, 12-aqueous disodium hydrogen phosphate and sodium dihydrogen phosphate, whereas each of the liposomes represents a hollow coating containing lecithin, cholesterol and alpha-tocopherol, and a nucleus inside the coating and containing recombinant human interferon alpha-2; the ingredients of the agents are taken in a certain ratio, mg.

EFFECT: maintaining the storage activity of recombinant human interferon alpha-2 and prolonged action in vaginal application.

2 cl, 3 dwg, 6 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention provides a composition having antioxidant properties in the form of a tablet, comprising an active agent based on nicotinamide adenine dinucleotide in reduced form (NADH) and inert filling agents, characterised by that the active ingredient is a complex which is a mixture of 10 wt % NADH with 63 wt % vegetable fats, 17 wt % beeswax and 10 wt % chlorophyll, and the inert filling agents are in the form of microcrystalline cellulose, Macrogol 6000, intense sweetener and a food flavourant.

EFFECT: invention provides a new tablet form of NADH.

1 ex

FIELD: medicine.

SUBSTANCE: method implies using Cytoflavinum 10 ml in physiological saline 200 ml twice a day every 12 hours for 3 preoperative days and once intraoperatively. The above therapeutic regimen enables correcting endogenous intoxication effectively and compensating underlying respiratory disorders in the patients suffering colorectal cancer.

EFFECT: reducing rate and intensity of the respiratory disorders with underlying reduced degree of endogenous intoxication in the patients prior to the coming surgical management of colorectal cancer.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine, namely to pharmaceutical industry and deals with solid pharmaceutical composition, possessing high physical strength. Claimed invention also presents method of manufacturing solid pharmaceutical composition. Claimed pharmaceutical composition contains 7 varicoloured types of granules in form of capsule. Granules contain, wt %: nikotinamide 1-35; pyridoxine 0.1-8; calcium pantitenate 0.1-15, thiamin 0.1-30; tryptophan 1-30; tocoferol 0.5-5; ascorbic acid 0.1-50; 5-hydroxyanthranyl acid 0.01-10; Riboflavin 0.1-10; folic acid 0.1-6; cyanocobalomin 0.001-6; isoleucin 0.5-10; leucin 0.5-15; lysine 0.5-20; phenylalanine 0.1-5; threonine 0.1-5.0; valin 0.1-8.0; methionine 0.1-15; lactose 1-4.0; ergocalcioferol 1-95.0 and auxiliary substances for obtaining granules.

EFFECT: claimed composition possesses excellent properties of medication release and digectionin application composition possesses hepatoprotective hypolipidemic immunostimulating and normalising kidney activity action.

2 cl. 2 ex. 5 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pulmonology, and can be used for treatment of bronchopulmonary diseases. For this purpose traditional drug treatment of pathology is carried out, additionally performed is impact by infrared laser radiation (IRLR) and successive inhalation of mineral water aerosols. Impact by infrared laser radiation is performed on projection of bronchi and lungs with total superficial energy density 0.06-0.65 J/cm2 for 4-8 minutes per 1 procedure. For inhalation used are aerosols of mineral water in dose 6-15 ml with temperature 40-42°C. Inhalation is performed for 4-10 minutes per 1 procedure. Course of therapy constitutes 7-12 daily performed procedures.

EFFECT: method ensures increase of treatment efficiency due to effect of synergistic effect on cell elements and walls of bronchi as a result of photoionophoresis, namely quantum modification of membrane of epithelium cells, activation of state of ion channels, and therefore selective permeability of ion channels in the following inhalation, which ensures enhancement of ion diffusion into tissues of bronchi and lungs, intracellular and intercellular exchange.

8 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and concerns mediated PHKi inhibition of RHO-kinase for treating ophthalmic disorders. The substance of the invention involves RNA-interference for mRNA Rho-kinase expression inhibition for treating patients with ophthalmic disorders, especially for treating intraocular pressure, eye hypertension and glaucoma The mRNA Rho-kinase targets include gene ROCK 1 mRNA.

EFFECT: creation of the agent exhibiting improved properties.

56 cl, 2 ex, 4 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: medication represents derivatives of nucleotides of general formula (I)

, where X is H or OR1; one or two of substituents R1, R2, R3 are monosaccharide residues, the remaining ones are hydrogen protons; B is nitrous base bound in α- or β-position.

EFFECT: obtaining medication for inhibiting human enzyme poly(ADP-ribose)polymerase-1.

1 cl, 1 tbl, 2 dwg, 6 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes an agent comprising the following components, mg: 2-ethyl-6-methyl-oxypyridine succinate, 25-1500; nicotinamide adenine dinucleotide, 0.5-100, and inositol, 100-1200. Agent can comprise additionally L-carnitine in the amount 10-100 mg. Also, agent can comprise additionally choline alphoscerate in the amount 50-1000 mg. Agent can be prepared in injection or tabletted medicinal formulation or as suppository. Agent provides effective delaying apoptosis and arresting transformation of apoptotic alterations to necrotic alterations in pathological processes of different etiology.

EFFECT: valuable properties and enhanced effectiveness of agent.

4 cl, 2 dwg, 2 tbl, 9 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a medicinal agent used in arresting syndrome of systemic inflammatory response. Agent comprises, mg: diphosphopyridine nucleotide, 0.3-100 and inosine, 40.0-1200. Proposed medicinal agent can comprise additionally inhibitor of angiotensin-converting enzyme, mainly, lisinopril, 2.5-100 and cardiac glycoside, mainly, digoxin, 0.07-0.3. The new medicinal agent possesses the capacity for arresting syndrome of systemic inflammatory response being independently of etiology of its rise, and allows obtaining the expressed and stable curative effect for short times.

EFFECT: improved and valuable properties of medicinal agent.

5 cl, 4 tbl, 4 ex

The invention relates to medicine, namely to the dentist, can be used for the treatment of periodontitis

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a combination of leucine source and ω-3 polyunsaturated fatty acid source applicable in therapeutic or preventive treatment of hypercalcemia.

EFFECT: invention provides extending the range of products applicable in the therapeutic or preventive treatment of hypercalcemia.

19 cl, 8 dwg, 2 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with stable composition for provision of subject with therapeutically or prophylactically effective amount of alpha-1 protease inhibitor (API), containing alpha-1 protease inhibitor (API) and at least one amino acid, selected from alanine, threonine, serine or hydroxyproline, where said composition includes one or more auxiliary substances, where at least one amino acid is present in composition in the total amount of amino acid from approximately 0.01 M to approximately 3 M. Group of inventions also deals with set for treatment or prevention of API-associated disease or condition, which includes said composition; application of at least one amino acid, selected from alanine, threonine, serine or hydroxyproline, for stabilisation of composition, containing alpha-1 protease inhibitor (API).

EFFECT: group of inventions provides stability of API composition.

15 cl, 27 dwg, 5 tbl, 8 ex

Up!